Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112852 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL3245514 | 0.94 | CYP2A6 (0.47) | CYP2A6ALDH1A1ALOX15MAPK1TDP1 | |
| Fluoride Ion SCHEMBL4307159 | 0.92 | CYP2A6 (0.44) | CYP2A6ALDH1A1ALOX15MAPK1TDP1 | |
| SCHEMBL236958 | 0.87 | CYP2A6 (0.40) | CYP2A6ALDH1A1ALOX15MAPK1 | |
| SCHEMBL3238117 | 0.83 | CYP2A6 (0.36) | CYP2A6FAAHMGLLCA1CA2 | |
| SCHEMBL809429 | 0.83 | CYP2A6 (0.36) | CYP2A6CA1CA2TSHR | |
| Hydrochloric Acid SCHEMBL9017439 | 0.81 | RAPGEF4 (0.38) | CYP2A6ALDH1A1ALOX15MAPK1TDP1 | |
| SCHEMBL1304591 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL11205797 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL15015513 | 0.76 | ALDH1A1 (0.50) | CYP2A6ALDH1A1ALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5371238-A | Reacting 1-/n-alkenyl/-azacycloalkan-2-one with alkyl mercaptan using free radical initiator, reducing, distilling to purify | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1994-12-06 | — | — | US | claimed |
| EP-4487918-B1 | AMPHIPHILIC POLYMERS AND THEIR USE FOR IMPROVED PRODUCTION OF NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS | TOPAS THERAPEUTICS GMBH (DE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4487918-A2 | AMPHIPHILIC POLYMERS AND THEIR USE FOR IMPROVED PRODUCTION OF NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS | Topas Therapeutics GmbH (DE) | 2025-01-08 | — | — | EP | disclosed |
| CN-119185207-A | Amphiphilic polymers and their use for improved production of nanoparticles for antigen-targeted delivery | TOPAS医疗科技有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240424089-A1 | Pharmaceutical Composition Comprising Nanoparticles for the Targeted Delivery of Antigens | TOPAS THERAPEUTICS GMBH (DE) | 2024-12-26 | — | — | US | disclosed |
| US-20240293575-A1 | NANOPARTICLES COMPRISING PEPTIDES INCLUDING AN N-TERMINAL LINKER | TOPAS THERAPEUTICS GMBH (DE) | 2024-09-05 | — | — | US | disclosed |
| EP-4106729-B1 | AMPHIPHILIC POLYMERS AND THEIR USE FOR IMPROVED PRODUCTION OF NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS | TOPAS THERAPEUTICS GMBH (DE) | 2024-08-14 | — | — | EP | disclosed |
| EP-3532580-B1 | USE AND METHOD COMPRISING A LUBRICATING OIL COMPOSITIONS COMPRISING BIODIESEL FUEL AND A DISPERSANT | CHEVRON ORONITE TECH BV (NL) | 2024-07-03 | — | — | EP | disclosed |
| EP-4387590-A2 | PHARMACEUTICAL COMPOSITION COMPRISING NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS | Topas Therapeutics GmbH (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-12016931-B2 | Nanoparticles comprising peptides including an n-terminal linker | TOPAS THERAPEUTICS GMBH (DE) | 2024-06-25 | — | — | US | disclosed |
| WO-1990003359-A1 | NOVEL POLYMERIC DISPERSANTS HAVING ALTERNATING POLYALKYLENE AND SUCCINIC GROUPS | CHEVRON RESEARCH COMPANY (US) | 1990-04-05 | — | — | WO | disclosed |
| US-4871823-A | HYDROPHILIC | S. C. JOHNSON & SON, INC. (US) | 1989-10-03 | — | — | US | disclosed |
| US-4859752-A | Alkene/excess maleic anhydride polymer manufacture | S. C. JOHNSON & SON, INC. (US) | 1989-08-22 | — | — | US | disclosed |
| US-4849489-A | Continuous process and system for producing polymers comprising maleic anhydride and certain alpha-olefins | S. C. JOHNSON & SON, INC. (US) | 1989-07-18 | — | — | US | disclosed |
| EP-0306992-A2 | 1-alkene/excess maleic anhydride polymers | S.C. JOHNSON & SON, INC. (US) | 1989-03-15 | — | — | EP | disclosed |
| EP-0306991-A2 | A method for making 1-alkene/excess maleic anhydride polymers | S.C. JOHNSON & SON, INC. (US) | 1989-03-15 | — | — | EP | disclosed |
| EP-0303057-A2 | Continous process and system for producing polymers maleic anhydride & certain alpha-olefins | S.C. JOHNSON & SON, INC. (US) | 1989-02-15 | — | — | EP | disclosed |
| US-4526950-A | Method for preparing interpolymers | THE LUBRIZOL CORPORATION (US) | 1985-07-02 | — | — | US | disclosed |
| US-4070295-A | Sulfone copolymeric additive for hydrocarbon oils | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1978-01-24 | — | — | US | disclosed |
| US-4014662-A | ETHYLENE POLYMERS | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293575-A1 | NANOPARTICLES COMPRISING PEPTIDES INCLUDING AN N-TERMINAL LINKER | MICA, HLA-DRB1, CD74 | CYP2A6 3934/4885ALDH1A1 4376/4885ALOX15 2807/4885 |
| US-12016931-B2 | Nanoparticles comprising peptides including an n-terminal linker | MICA, HLA-DRB1, CD74 | CYP2A6 3934/4885ALDH1A1 4376/4885ALOX15 2807/4885 |
| US-20240424089-A1 | Pharmaceutical Composition Comprising Nanoparticles for the Targeted Delivery of Antigens | DSG1, MICA, HLA-DRB1 | CYP2A6 4249/4885ALDH1A1 4684/4885ALOX15 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.